Predicting Alzheimer's disease subtypes and understanding their molecular characteristics in living patients with transcriptomic trajectory profiling

dc.contributor.authorHuang, Xiaoqing
dc.contributor.authorJannu, Asha Jacob
dc.contributor.authorSong, Ziyan
dc.contributor.authorJury-Garfe, Nur
dc.contributor.authorLasagna-Reeves, Cristian A.
dc.contributor.authorAlzheimer’s Disease Neuroimaging Initiative
dc.contributor.authorJohnson, Travis S.
dc.contributor.authorHuang, Kun
dc.contributor.authorZhang, Jie
dc.contributor.departmentBiostatistics and Health Data Science, Richard M. Fairbanks School of Public Health
dc.date.accessioned2025-02-18T09:39:53Z
dc.date.available2025-02-18T09:39:53Z
dc.date.issued2025
dc.description.abstractIntroduction: Deciphering the diverse molecular mechanisms in living Alzheimer's disease (AD) patients is a big challenge but is pivotal for disease prognosis and precision medicine development. Methods: Utilizing an optimal transport approach, we conducted graph-based mapping of transcriptomic profiles to transfer AD subtype labels from ROSMAP monocyte samples to ADNI and ANMerge peripheral blood mononuclear cells. Subsequently, differential expression followed by comparative pathway and diffusion pseudotime analysis were applied to each cohort to infer the progression trajectories. Survival analysis with real follow-up time was used to obtain potential biomarkers for AD prognosis. Results: AD subtype labels were accurately transferred onto the blood samples of ADNI and ANMerge living patients. Pathways and associated genes in neutrophil degranulation-like immune process, immune acute phase response, and IL-6 signaling were significantly associated with AD progression. Discussion: The work enhanced our understanding of AD progression in different subtypes, offering insights into potential biomarkers and personalized interventions for improved patient care. Highlights: We applied an innovative optimal transport-based approach to map transcriptomic data from different Alzheimer's disease (AD) cohort studies and transfer known AD subtype labels from ROSMAP monocyte samples to peripheral blood mononuclear cell (PBMC) samples within ADNI and ANMerge cohorts. Through comprehensive trajectory and comparative analysis, we investigated the molecular mechanisms underlying different disease progression trajectories in AD. We validated the accuracy of our AD subtype label transfer and identified prognostic genetic markers associated with disease progression, facilitating personalized treatment strategies. By identifying and predicting distinctive AD subtypes and their associated pathways, our study contributes to a deeper understanding of AD heterogeneity.
dc.eprint.versionFinal published version
dc.identifier.citationHuang X, Jannu AJ, Song Z, et al. Predicting Alzheimer's disease subtypes and understanding their molecular characteristics in living patients with transcriptomic trajectory profiling. Alzheimers Dement. 2025;21(1):e14241. doi:10.1002/alz.14241
dc.identifier.urihttps://hdl.handle.net/1805/45771
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1002/alz.14241
dc.relation.journalAlzheimer's & Dementia
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.sourcePMC
dc.subjectAD prognosis
dc.subjectAD subtyping
dc.subjectADNI
dc.subjectANMerge
dc.subjectDisease progression
dc.subjectOptimal transport
dc.subjectROSMAP
dc.subjectSex‐specific difference
dc.subjectTrajectory pseudotime
dc.titlePredicting Alzheimer's disease subtypes and understanding their molecular characteristics in living patients with transcriptomic trajectory profiling
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Huang2025Predicting-CCBYNCND.pdf
Size:
4.12 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: